Healionics

Healionics Corporation develops engineered biomaterials and medical devices aimed at improving outcomes in patients requiring long-term bloodstream access—primarily those undergoing dialysis due to kidney failure. Its lead product line leverages the proprietary STAR® platform—a unique porous material that promotes tissue integration while resisting scarring and infection—to create safer synthetic blood vessels (vascular grafts) under the brand STARgraft. This approach addresses major complications seen with current devices such as occlusion or infection. The company has also enabled commercial products outside nephrology through its spinoffs—for example a glaucoma drainage device now approved in Europe through iSTAR Medical. Healionics remains privately held with headquarters in Seattle and maintains strong academic ties within the region’s biomedical innovation ecosystem.